Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Aroa Biosurgery Ltd

Healthcare AU ARX

0.575AUD
-(-%)

Last update at 2025-07-11T03:47:00Z

Day Range

0.570.58
LowHigh

52 Week Range

0.350.81
LowHigh

Fundamentals

  • Previous Close 0.57
  • Market Cap198.91M
  • Volume27142
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA0.26M
  • Revenue TTM84.70M
  • Revenue Per Share TTM0.25
  • Gross Profit TTM 72.61M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -0.35945M -7.67822M -17.53603M -6.16000M -3.04700M
Minority interest - - - - -
Net income -0.37068M -7.79440M -17.63426M -5.95800M 0.96M
Selling general administrative 47.71M 28.54M 19.98M 16.67M 11.86M
Selling and marketing expenses 44.66M 28.54M 19.98M - -
Gross profit 50.06M 28.17M 14.25M 18.74M 16.31M
Reconciled depreciation 3.59M 2.91M 2.83M - -
Ebit -0.35383M -6.98113M -16.15808M -2.84300M 0.88M
Ebitda 3.24M -4.07101M -13.33150M - -
Depreciation and amortization 3.59M 2.91M 2.83M - -
Non operating income net other - - - - -
Operating income -0.35383M -6.98113M -16.15808M -2.84300M 0.88M
Other operating expenses 67.44M 47.93M 34.96M 0.13M 0.19M
Interest expense 0.00562M 0.70M 1.38M 1.01M 0.00000M
Tax provision 0.01M 0.12M 0.10M -0.20200M -4.00700M
Interest income 2.73M 0.37M 0.14M 0.59M 1.27M
Net interest income 0.87M -0.69709M -1.75067M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.01M 0.12M 0.10M -0.20200M -4.00700M
Total revenue 59.31M 36.88M 20.51M 25.08M 23.32M
Total operating expenses 58.19M 39.22M 28.70M - 5.73M
Cost of revenue 9.25M 8.72M 6.26M 6.34M 7.00M
Total other income expense net 3.30M 1.16M -4.30460M - -0.16657M
Discontinued operations - - - - -
Net income from continuing ops -0.37068M -7.79440M -17.63426M - -5.89237M
Net income applicable to common shares -0.39600M -8.38600M -19.20900M -5.95800M 0.96M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 98.94M 101.82M 109.07M 104.71M 73.12M
Intangible assets 12.33M - 11.31M 10.90M 11.51M
Earning assets - - - - -
Other current assets 17.00M 1.66M 10.36M 1.23M 18.36M
Total liab 14.35M 14.78M 13.69M 11.30M 19.43M
Total stockholder equity 84.59M 87.04M 95.38M 93.40M 53.69M
Deferred long term liab - - 1.33M - -
Other current liab - 6.24M 5.10M 4.45M 3.70M
Common stock - 134.59M 137.13M 135.47M 89.34M
Capital stock 133.44M - 137.13M 135.47M 89.34M
Retained earnings -58.21338M -56.98378M -48.22990M -47.52115M -39.23804M
Other liab - - - 0.16M 0.16M
Good will 5.03M 5.08M 5.18M 5.15M 5.08M
Other assets - - 0.13M 0.15M 0.17M
Cash 7.26M 10.56M 8.93M 5.73M 14.12M
Cash and equivalents - - - - -
Total current liabilities 9.36M 8.72M 7.41M 6.24M 14.04M
Current deferred revenue - 0.00000M - - -
Net debt - -3.74715M -2.27745M -0.26861M 0.78M
Short term debt - 0.92M 0.52M 0.55M 9.66M
Short long term debt - - - - 9.14M
Short long term debt total - 6.82M 6.65M 5.46M 14.90M
Other stockholder equity - 0.00000M 0.00000M 5.86M 3.91M
Property plant equipment - - 20.64M 15.36M 12.66M
Total current assets 61.95M 63.29M 73.14M 74.24M 44.75M
Long term investments - - - - -
Net tangible assets - - 85.60M 83.22M 40.41M
Short term investments 12.87M 17.15M 34.07M 47.62M 19.81M
Net receivables 13.82M 26.49M 13.41M 15.96M 6.60M
Long term debt - - - - 0.00000M
Inventory 7.52M 7.43M 4.52M 3.70M 3.31M
Accounts payable 1.51M 1.57M 1.79M 1.24M 0.68M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 9.44M 6.48M 5.45M 3.59M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.07M 13.08M 0.12M 0.14M 0.16M
Deferred long term asset charges - - - - -
Non current assets total 36.98M 38.53M 35.93M 30.46M 28.37M
Capital lease obligations 5.83M - 6.65M 5.46M 5.77M
Long term debt total - - 6.55M 5.29M 5.72M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments 6.79M -30.00000M -20.00000M -20.00000M -20.00000M
Change to liabilities - 1.32M -0.29800M 2.27M 0.73M
Total cashflows from investing activities 7.25M -34.87100M -21.50000M -1.87000M -3.70500M
Net borrowings - -10.08900M -12.91800M -6.10200M -4.73000M
Total cash from financing activities -0.47178M 34.98M 34.06M -0.38400M 4.13M
Change to operating activities - -1.33700M -0.82600M -0.02600M -0.08300M
Net income -0.37068M -8.38600M -19.20900M -5.95800M 0.96M
Change in cash 3.16M -8.56585M 10.59M -0.60700M 0.58M
Begin period cash flow 5.77M 14.30M 3.53M - -
End period cash flow 8.93M 5.73M 14.12M 3.53M -
Total cash from operating activities -3.77200M -11.52200M -5.00700M 1.66M -0.00700M
Issuance of capital stock 0.49M 46.77M 32.09M - -
Depreciation - 3.13M 3.05M 2.72M 2.06M
Other cashflows from investing activities 14.87M -30.00000M -20.00000M -20.00000M -20.00000M
Dividends paid - - 18.18M - -
Change to inventory - -0.32300M 0.63M -1.32700M -0.88900M
Change to account receivables - -10.38800M -0.48900M -1.67500M -2.66100M
Sale purchase of stock -0.95853M -2.05781M -3.97411M 0.30M 8.87M
Other cashflows from financing activities 0.00000M -0.89506M 17.51M 5.42M 5.42M
Change to netincome - 4.32M 10.12M 6.01M -0.39200M
Capital expenditures 7.12M 4.53M 1.38M 1.69M 1.56M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.17M 0.14M 0.13M 0.00400M 0.00400M
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -7.12440M -4.52737M -1.37703M - -

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARX
Aroa Biosurgery Ltd		 - -% 0.57 - 78.12 2.35 2.37 2.42 70.42
COH
Cochlear Ltd		 0.72 0.24% 303.48 53.83 45.05 8.60 10.61 8.53 32.95
PNV
Polynovo Ltd		 - -% 1.14 115.00 54.35 6.90 10.43 6.70 84.20
EBR
Ebr Systems Inc CDR		 0.005 0.43% 1.16 - - - 19.31 -3.6785
IMR
Imricor Medical Systems Inc		 -0.055 4.17% 1.26 - - 422.51 3.97 293.49 -2.6027

Reports Covered

Stock Research & News

View All

Profile

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Aroa Biosurgery Ltd

64 Richard Pearse Drive, Auckland, New Zealand, 2022

Key Executives

Name Title Year Born
Dr. Brian Ward Founder, CEO, MD & Exec. Director NA
Mr. James Agnew BCom, LLB CFO & Joint Company Sec. NA
Dr. Barnaby C.H. May Ph.D. Chief Scientific Officer NA
Ms. Tracy Weimar BA, MBA Company Sec. NA
Dr. Brian Ward Founder, CEO, MD & Executive Director NA
Mr. James Agnew BCom, LLB CFO & Joint Company Secretary NA
Mr. Scott Sherriff B.A., M.B.A. Chief Operating Officer NA
Ms. Neetha Alex-Kumar General Counsel NA
Mr. Frazer Murray Director of Global Marketing & Strategy NA
Ms. Yasmin Winchester B.Sc. Vice President of Quality, Regulatory & Sustainability NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.